Resources

By Featured Writer Sheri R. Colberg, PhD. As a clinical exercise researcher, I frequently have found it difficult to study exercise effects in people with health complications, even though this is critical information to know in order to make appropriate exercise guidelines. Try convincing your university Institutional Research Board, or IRB, that it is advisable to exercise people with eye issues like unstable proliferative retinopathy to find out if breath-holding, jumping, jarring, or head-down activities cause them to experience retinal hemorrhages. Understandably, that is not going to happen, nor should it.

One of your patients is currently taking metformin, glyburide, and an evening basal dose of insulin. After discussing how best to achieve better glycemic control, he has agreed to add a pre-meal insulin dose. Which modification should be made with the addition of the prandial dose? A. Discontinue the glyburide B. Discontinue the metformin C. No modifications should be made D. Discontinue the metformin, glyburide, and evening insulin Follow the link for the correct answer.

For a 2nd add-on drug to prescribe to those with type 2 diabetes and who are not meeting either an A1c goal of 6% or less, or an A1c of 7.5% with no complications, which might you prefer to add on to metformin to reach the goal of 6%? 1. DPP-4 Inhibitor 2. SGLT-2 Inhibitor 3. TZD 4. Sulfonylurea 5. Dopamine receptor agonist 6. GLP-1 Agonists Follow the link to share your response.

Dr. Mark Molitch is the Martha Leland Sherwin Professor of Medicine at Northwestern in the Division of Endocrinology, Metabolism and Molecular Medicine. Dr. Molitch has been active in clinical research in diabetes, focusing on diabetic nephropathy, and other areas of endocrinology.

In this Exclusive Interview, Dr. Mark Molitch talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about how doctors can educate patients on nutrition and diet issues, the advances in diabetes technology, and the complexities of diabetes multi-drug therapies.

Transcript coming soon.

In part 1 of this Exclusive Interview, Dr. Mark Molitch talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about teaching medical students about the specifics of nutrition as it relates to diabetes management.

In part 2 of this Exclusive Interview, Dr. Mark Molitch shares his thoughts about technology, the latest meds, and what's coming down the pike in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 3 of this Exclusive Interview, Dr. Mark Molitch talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about his ADA presentation on resulting diabetes diagnoses or hyperglycemia following islet pancreatic transplant surgery.

In part 4 of this Exclusive Interview, Dr. Mark Molitch shares his thoughts on the latest diabetes drug class, SGLT2, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.